{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:18:50Z","timestamp":1787653130113,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404337, 82170870, and 82120108008"],"award-info":[{"award-number":["82404337, 82170870, and 82120108008"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-026-03304-y","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:17:07Z","timestamp":1784733427000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genetically proxied glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor pathway modulation is associated with favorable aging phenotypes: a drug-target Mendelian randomization study"],"prefix":"10.1186","volume":"25","author":[{"given":"Jiang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningjian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingli","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4869-1352","authenticated-orcid":false,"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"3304_CR1","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","volume":"153","author":"C L\u00f3pez-Ot\u00edn","year":"2013","unstructured":"L\u00f3pez-Ot\u00edn C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153:1194\u2013217. https:\/\/doi.org\/10.1016\/j.cell.2013.05.039.","journal-title":"Cell"},{"key":"3304_CR2","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1016\/j.cell.2023.08.003","volume":"186","author":"M Moqri","year":"2023","unstructured":"Moqri M, et al. Biomarkers of aging for the identification and evaluation of longevity interventions. Cell. 2023;186:3758\u201375. https:\/\/doi.org\/10.1016\/j.cell.2023.08.003.","journal-title":"Cell"},{"key":"3304_CR3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.cell.2014.10.039","volume":"159","author":"BK Kennedy","year":"2014","unstructured":"Kennedy BK, et al. Geroscience: linking aging to chronic disease. Cell. 2014;159:709\u201313. https:\/\/doi.org\/10.1016\/j.cell.2014.10.039.","journal-title":"Cell"},{"key":"3304_CR4","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2337\/dci24-0003","volume":"47","author":"DJ Drucker","year":"2024","unstructured":"Drucker DJ. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care. 2024;47:1873\u201388. https:\/\/doi.org\/10.2337\/dci24-0003.","journal-title":"Diabetes Care"},{"key":"3304_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103363","volume":"86","author":"A Moiz","year":"2025","unstructured":"Moiz A, et al. The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions. EClinicalMedicine. 2025;86:103363. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103363.","journal-title":"EClinicalMedicine"},{"key":"3304_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9:234. https:\/\/doi.org\/10.1038\/s41392-024-01931-z.","journal-title":"Signal Transduct Target Ther"},{"key":"3304_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2026.156547","volume":"178","author":"M Li","year":"2026","unstructured":"Li M, Xu S, Cai H, Xiao J, Qin Y. The multifaceted role of GLP-1 in metabolic disorders, chronic inflammation, and aging: mechanisms and therapeutic potential. Metabolism. 2026;178:156547. https:\/\/doi.org\/10.1016\/j.metabol.2026.156547.","journal-title":"Metabolism"},{"key":"3304_CR8","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/s41467-025-67622-7","volume":"17","author":"J Li","year":"2025","unstructured":"Li J, et al. Social determinants of health, accelerated biological aging, and long-term health outcomes. Nat Commun. 2025;17:900. https:\/\/doi.org\/10.1038\/s41467-025-67622-7.","journal-title":"Nat Commun"},{"key":"3304_CR9","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/s2468-2667(19)30019-2","volume":"4","author":"AY Chang","year":"2019","unstructured":"Chang AY, Skirbekk VF, Tyrovolas S, Kassebaum NJ, Dieleman JL. Measuring population ageing: an analysis of the Global Burden of Disease Study 2017. Lancet Public Health. 2019;4:e159\u201367. https:\/\/doi.org\/10.1016\/s2468-2667(19)30019-2.","journal-title":"Lancet Public Health"},{"key":"3304_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2025.10.014","author":"J Huang","year":"2025","unstructured":"Huang J, et al. Body-wide multi-omic counteraction of aging with GLP-1R agonism. Cell Metab. 2025. https:\/\/doi.org\/10.1016\/j.cmet.2025.10.014.","journal-title":"Cell Metab"},{"key":"3304_CR11","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.2337\/dbi24-0026","volume":"74","author":"RJ Samms","year":"2025","unstructured":"Samms RJ, Sloop KW. A contemporary rationale for agonism of the GIP receptor in the treatment of obesity. Diabetes. 2025;74:1326\u201333. https:\/\/doi.org\/10.2337\/dbi24-0026.","journal-title":"Diabetes"},{"key":"3304_CR12","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503\u201315. https:\/\/doi.org\/10.1056\/NEJMoa2107519.","journal-title":"N Engl J Med"},{"key":"3304_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393:26\u201336. https:\/\/doi.org\/10.1056\/NEJMoa2416394.","journal-title":"N Engl J Med"},{"key":"3304_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s43586-021-00092-5","author":"E Sanderson","year":"2022","unstructured":"Sanderson E, et al. Mendelian randomization. Nat Rev Methods Primers. 2022. https:\/\/doi.org\/10.1038\/s43586-021-00092-5.","journal-title":"Nat Rev Methods Primers"},{"key":"3304_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16969-0","volume":"11","author":"AF Schmidt","year":"2020","unstructured":"Schmidt AF, et al. Genetic drug target validation using Mendelian randomisation. Nat Commun. 2020;11:3255. https:\/\/doi.org\/10.1038\/s41467-020-16969-0.","journal-title":"Nat Commun"},{"key":"3304_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-02019-8","volume":"22","author":"J Li","year":"2023","unstructured":"Li J, et al. SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study. Cardiovasc Diabetol. 2023;22:278. https:\/\/doi.org\/10.1186\/s12933-023-02019-8.","journal-title":"Cardiovasc Diabetol"},{"key":"3304_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2233","volume":"375","author":"VW Skrivankova","year":"2021","unstructured":"Skrivankova VW, et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration. BMJ. 2021;375:n2233. https:\/\/doi.org\/10.1136\/bmj.n2233.","journal-title":"BMJ"},{"key":"3304_CR18","doi-asserted-by":"publisher","DOI":"10.1126\/science.adj1182","volume":"385","author":"A Verma","year":"2024","unstructured":"Verma A, et al. Diversity and scale: genetic architecture of 2068 traits in the VA Million Veteran Program. Science. 2024;385:eadj1182. https:\/\/doi.org\/10.1126\/science.adj1182.","journal-title":"Science"},{"key":"3304_CR19","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41586-022-05473-8","volume":"613","author":"MI Kurki","year":"2023","unstructured":"Kurki MI, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature. 2023;613:508\u201318. https:\/\/doi.org\/10.1038\/s41586-022-05473-8.","journal-title":"Nature"},{"key":"3304_CR20","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1093\/hmg\/ddy271","volume":"27","author":"L Yengo","year":"2018","unstructured":"Yengo L, et al. Meta-analysis of genome-wide association studies for height and body mass index in \u223c700000 individuals of European ancestry. Hum Mol Genet. 2018;27:3641\u20139. https:\/\/doi.org\/10.1093\/hmg\/ddy271.","journal-title":"Hum Mol Genet"},{"key":"3304_CR21","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","volume":"20","author":"JR Ussher","year":"2023","unstructured":"Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023;20:463\u201374. https:\/\/doi.org\/10.1038\/s41569-023-00849-3.","journal-title":"Nat Rev Cardiol"},{"key":"3304_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","volume":"21","author":"TD M\u00fcller","year":"2022","unstructured":"M\u00fcller TD, Bl\u00fcher M, Tsch\u00f6p MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21:201\u201323. https:\/\/doi.org\/10.1038\/s41573-021-00337-8.","journal-title":"Nat Rev Drug Discov"},{"key":"3304_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2206038.","journal-title":"N Engl J Med"},{"key":"3304_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25731-z","volume":"12","author":"M Gordillo-Mara\u00f1\u00f3n","year":"2021","unstructured":"Gordillo-Mara\u00f1\u00f3n M, et al. Validation of lipid-related therapeutic targets for coronary heart disease prevention using human genetics. Nat Commun. 2021;12:6120. https:\/\/doi.org\/10.1038\/s41467-021-25731-z.","journal-title":"Nat Commun"},{"key":"3304_CR25","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1161\/circulationaha.121.056663","volume":"145","author":"A Henry","year":"2022","unstructured":"Henry A, et al. Therapeutic targets for heart failure identified using proteomics and Mendelian randomization. Circulation. 2022;145:1205\u201317. https:\/\/doi.org\/10.1161\/circulationaha.121.056663.","journal-title":"Circulation"},{"key":"3304_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d7771","volume":"344","author":"T Vilsb\u00f8ll","year":"2012","unstructured":"Vilsb\u00f8ll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771. https:\/\/doi.org\/10.1136\/bmj.d7771.","journal-title":"BMJ"},{"key":"3304_CR27","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nrendo.2012.140","volume":"8","author":"JJ Meier","year":"2012","unstructured":"Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728\u201342. https:\/\/doi.org\/10.1038\/nrendo.2012.140.","journal-title":"Nat Rev Endocrinol"},{"key":"3304_CR28","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41586-024-07019-6","volume":"627","author":"K Suzuki","year":"2024","unstructured":"Suzuki K, et al. Genetic drivers of heterogeneity in type 2 diabetes pathophysiology. Nature. 2024;627:347\u201357. https:\/\/doi.org\/10.1038\/s41586-024-07019-6.","journal-title":"Nature"},{"key":"3304_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2318-8-24","volume":"8","author":"SD Searle","year":"2008","unstructured":"Searle SD, Mitnitski A, Gahbauer EA, Gill TM, Rockwood K. A standard procedure for creating a frailty index. BMC Geriatr. 2008;8:24. https:\/\/doi.org\/10.1186\/1471-2318-8-24.","journal-title":"BMC Geriatr"},{"key":"3304_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002718","volume":"15","author":"Z Liu","year":"2018","unstructured":"Liu Z, et al. A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: a cohort study. PLoS Med. 2018;15:e1002718. https:\/\/doi.org\/10.1371\/journal.pmed.1002718.","journal-title":"PLoS Med"},{"key":"3304_CR31","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/nm1006-1133","volume":"12","author":"EH Blackburn","year":"2006","unstructured":"Blackburn EH, Greider CW, Szostak JW. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat Med. 2006;12:1133\u20138. https:\/\/doi.org\/10.1038\/nm1006-1133.","journal-title":"Nat Med"},{"key":"3304_CR32","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1038\/s41467-019-11558-2","volume":"10","author":"J Deelen","year":"2019","unstructured":"Deelen J, et al. A meta-analysis of genome-wide association studies identifies multiple longevity genes. Nat Commun. 2019;10:3669. https:\/\/doi.org\/10.1038\/s41467-019-11558-2.","journal-title":"Nat Commun"},{"key":"3304_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13459","volume":"20","author":"JL Atkins","year":"2021","unstructured":"Atkins JL, et al. A genome-wide association study of the frailty index highlights brain pathways in ageing. Aging Cell. 2021;20:e13459. https:\/\/doi.org\/10.1111\/acel.13459.","journal-title":"Aging Cell"},{"key":"3304_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13376","volume":"20","author":"CL Kuo","year":"2021","unstructured":"Kuo CL, Pilling LC, Liu Z, Atkins JL, Levine ME. Genetic associations for two biological age measures point to distinct aging phenotypes. Aging Cell. 2021;20:e13376. https:\/\/doi.org\/10.1111\/acel.13376.","journal-title":"Aging Cell"},{"key":"3304_CR35","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1038\/s41588-024-01884-7","volume":"56","author":"OS Burren","year":"2024","unstructured":"Burren OS, et al. Genetic architecture of telomere length in 462,666 UK Biobank whole-genome sequences. Nat Genet. 2024;56:1832\u201340. https:\/\/doi.org\/10.1038\/s41588-024-01884-7.","journal-title":"Nat Genet"},{"key":"3304_CR36","doi-asserted-by":"publisher","DOI":"10.1172\/jci146353","author":"RJ Samms","year":"2021","unstructured":"Samms RJ, et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. J Clin Invest. 2021. https:\/\/doi.org\/10.1172\/jci146353.","journal-title":"J Clin Invest"},{"key":"3304_CR37","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.cmet.2023.07.010","volume":"35","author":"JE Campbell","year":"2023","unstructured":"Campbell JE, et al. GIPR\/GLP-1R dual agonist therapies for diabetes and weight loss-chemistry, physiology, and clinical applications. Cell Metab. 2023;35:1519\u201329. https:\/\/doi.org\/10.1016\/j.cmet.2023.07.010.","journal-title":"Cell Metab"},{"key":"3304_CR38","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/gerona\/62.7.722","volume":"62","author":"K Rockwood","year":"2007","unstructured":"Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. J Gerontol A Biol Sci Med Sci. 2007;62:722\u20137. https:\/\/doi.org\/10.1093\/gerona\/62.7.722.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"3304_CR39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/s2213-8587(24)00271-7","volume":"13","author":"SV Badve","year":"2025","unstructured":"Badve SV, et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2025;13:15\u201328. https:\/\/doi.org\/10.1016\/s2213-8587(24)00271-7.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3304_CR40","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.cell.2022.11.001","volume":"186","author":"C L\u00f3pez-Ot\u00edn","year":"2023","unstructured":"L\u00f3pez-Ot\u00edn C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. Cell. 2023;186:243\u201378. https:\/\/doi.org\/10.1016\/j.cell.2022.11.001.","journal-title":"Cell"},{"key":"3304_CR41","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1172\/jci81507","volume":"125","author":"U Smith","year":"2015","unstructured":"Smith U. Abdominal obesity: a marker of ectopic fat accumulation. J Clin Invest. 2015;125:1790\u20132. https:\/\/doi.org\/10.1172\/jci81507.","journal-title":"J Clin Invest"},{"key":"3304_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13806","volume":"25","author":"B Ahmed","year":"2024","unstructured":"Ahmed B, Farb MG, Gokce N. Cardiometabolic implications of adipose tissue aging. Obes Rev. 2024;25:e13806. https:\/\/doi.org\/10.1111\/obr.13806.","journal-title":"Obes Rev"},{"key":"3304_CR43","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf1066","author":"Y Hu","year":"2026","unstructured":"Hu Y, et al. GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization. Eur Heart J. 2026. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf1066.","journal-title":"Eur Heart J"},{"key":"3304_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2025.102298","volume":"103","author":"W Roell","year":"2026","unstructured":"Roell W, et al. Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: preclinical development and phase 1 randomized ascending dose studies. Mol Metab. 2026;103:102298. https:\/\/doi.org\/10.1016\/j.molmet.2025.102298.","journal-title":"Mol Metab"},{"key":"3304_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156057","volume":"161","author":"K Stefanakis","year":"2024","unstructured":"Stefanakis K, Kokkorakis M, Mantzoros CS. The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation. Metabolism. 2024;161:156057. https:\/\/doi.org\/10.1016\/j.metabol.2024.156057.","journal-title":"Metabolism"},{"key":"3304_CR46","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/14796678.2024.2433381","volume":"21","author":"G Santulli","year":"2025","unstructured":"Santulli G, Mone P, Varzideh F. GLP-1 receptor agonists and SGLT2 inhibitors: new anti-aging tools? Future Cardiol. 2025;21:5\u20138. https:\/\/doi.org\/10.1080\/14796678.2024.2433381.","journal-title":"Future Cardiol"},{"key":"3304_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanhl.2024.08.001","volume":"5","author":"P Mone","year":"2024","unstructured":"Mone P, et al. SGLT2 inhibitors and GLP-1 receptor agonists: which is the best anti-frailty drug? Lancet Healthy Longev. 2024;5:100632. https:\/\/doi.org\/10.1016\/j.lanhl.2024.08.001.","journal-title":"Lancet Healthy Longev"},{"key":"3304_CR48","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.ajhg.2022.04.001","volume":"109","author":"V Zuber","year":"2022","unstructured":"Zuber V, et al. Combining evidence from Mendelian randomization and colocalization: review and comparison of approaches. Am J Hum Genet. 2022;109:767\u201382. https:\/\/doi.org\/10.1016\/j.ajhg.2022.04.001.","journal-title":"Am J Hum Genet"},{"key":"3304_CR49","doi-asserted-by":"publisher","DOI":"10.1007\/s11357-025-01950-w","author":"J Li","year":"2025","unstructured":"Li J, et al. Glycemic status-dependent proteomic signatures of biological aging for health risk prediction. Geroscience. 2025. https:\/\/doi.org\/10.1007\/s11357-025-01950-w.","journal-title":"Geroscience"},{"key":"3304_CR50","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1038\/s41591-024-03164-7","volume":"30","author":"MA Argentieri","year":"2024","unstructured":"Argentieri MA, et al. Proteomic aging clock predicts mortality and risk of common age-related diseases in diverse populations. Nat Med. 2024;30:2450\u201360. https:\/\/doi.org\/10.1038\/s41591-024-03164-7.","journal-title":"Nat Med"},{"key":"3304_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52310-9","volume":"15","author":"S Zhang","year":"2024","unstructured":"Zhang S, et al. A metabolomic profile of biological aging in 250,341 individuals from the UK Biobank. Nat Commun. 2024;15:8081. https:\/\/doi.org\/10.1038\/s41467-024-52310-9.","journal-title":"Nat Commun"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-026-03304-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03304-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03304-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T09:22:18Z","timestamp":1787649738000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-026-03304-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3304"],"URL":"https:\/\/doi.org\/10.1186\/s12933-026-03304-y","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"19 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Summary-level GWAS statistics used in this study are publicly available and no specific ethical approval was required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"255"}}